Mithra jumps on positive results from Donesta late-stage trial

Mithra Pharmaceuticals SA

14/01/2022 08:47

** Shares in Mithra  MITRA.BR  rise 5.5% after the
Belgian-based biotech company published positive results from
Donesta Phase III trials in menopausal women
    ** The company says Donesta safety profile was confirmed by
end-year Data Safety Monitoring Board (DSMB), which recommended
to continue de Phase III clinical program as planned
    ** A "solid clinical results", writes KBC Securities in a
note, adding it expects the company to take a major step forward
in its trajectory
    ** "We look forward to more clarity on the drug's potential
commercialization and expect Mithra to strike a commercial deal
on the back of these results," the brokerage says
    ** Primary safety results are anticipated for end 2022 in
the United States/Canada and for end H1 2023 in Europe, the
company says

 (Reporting by Clement Martinot)
 ((Clement.martinot@tr.com))